Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1-178 |
| Number of pages | 178 |
| Journal | Health Technology Assessment |
| Volume | 15 |
| Issue number | 25 |
| DOIs | |
| Publication status | Published - 2011 |
Fingerprint
Cite this
Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day : a systematic review and economic evaluation. / Hislop, J; Quayyum, Z; Elders, A; Fraser, C; Jenkinson, D; Mowatt, G; Sharma, P; Vale, L; Petty, R.
In: Health Technology Assessment, Vol. 15, No. 25, 2011, p. 1-178.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day
T2 - a systematic review and economic evaluation
AU - Hislop, J
AU - Quayyum, Z
AU - Elders, A
AU - Fraser, C
AU - Jenkinson, D
AU - Mowatt, G
AU - Sharma, P
AU - Vale, L
AU - Petty, R
PY - 2011
Y1 - 2011
N2 - Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.
AB - Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.
U2 - 10.3310/hta15250
DO - 10.3310/hta15250
M3 - Article
C2 - 21689502
VL - 15
SP - 1
EP - 178
JO - Health Technology Assessment
JF - Health Technology Assessment
SN - 1366-5278
IS - 25
ER -